Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...

Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

The 2026 Shaffer Research Grants were awarded to Kun-Che Chang, PhD, Shruthi Karnam, PhD, Kate Keller, PhD, Naoki Kiyota, MD, PhD, Gillian McLellan, PhD, Kiyoharu Miyagishima, PhD, Kerstin Nundel, PhD ...

Certain diet and lifestyle measures, such as being physically active, may have beneficial effects on glaucoma, including improving blood flow to the eyes and lowering eye pressure. Herbal supplements ...

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Please provide your email address to receive an email when new articles are posted on . Consider angle morphology when treating patients with neovascular glaucoma. Comparable visual acuity and IOP and ...

Glaucoma often progresses silently, damaging vision before you even notice a problem. Experts warn that believing common myths can delay diagnosis and increase the risk of irreversible blindness.

Genomics can help to identify people who are more likely to develop glaucoma potentially long before any symptoms of the disease appear. Instead ...

A comanagement program at UCSF in which patients saw glaucoma-trained optometrists and had access to glaucoma specialists showed promising outcomes, according to a study published in Ophthalmology ...

Explore the silent thief of sight: glaucoma. This article sheds light on the urgent need for awareness and action to prevent ...